FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.